nach oben

Journal of Bone and Mineral Metabolism

Erschienen in:

08.08.2022 | Original Article

Risk factors for poor response to denosumab treatment in Japanese postmenopausal women with osteoporosis

verfasst von: Tokutaro Okawa, Motomi Okawa, Tatsuya Koike

Erschienen in: Journal of Bone and Mineral Metabolism | Ausgabe 6/2022

Einloggen, um Zugang zu erhalten

Abstract

Introduction

Denosumab has been reported to increase bone mineral density (BMD) and suppress fractures, but poor responders are not uncommon. This study aimed to identify risk factors for poor response to denosumab treatment. This is the first study to explore risk factors for poor response to denosumab.

Materials and methods

This retrospective observational study investigated 227 Japanese postmenopausal women who received denosumab with monitoring of BMD by dual-energy X-ray absorptiometry at 6-month intervals. Risk factors were identified using Cox’s proportional hazard modeling. Poor responders were defined as not exceeding the least significant change of BMD from baseline for 3 years.

Results

Mean relative change from baseline for 3 years in lumbar spine (LS)-BMD, femoral neck (FN)-BMD, and total hip (TH)-BMD were 12.6%, 6.8%, and 6.1%, respectively. Numbers of poor responders were 10 in LS-BMD, 47 in FN-BMD, 38 in TH-BMD. Risk factors for poor response were concomitant glucocorticoid use for LS-BMD, low body mass index or initiation at higher BMD for FN-BMD, and pretreatment with bisphosphonates or initiation at higher BMD for TH-BMD.

Conclusion

Risk factors for insufficient denosumab effect differed between BMD measurement sites. These results should be taken into consideration when selecting denosumab in clinical practice.

McCombs JS, Thiebaud P, McLaughlin-Miley C, Shi J (2004) Compliance with drug therapies for the treatment and prevention of osteoporosis. Maturitas 48:271–287CrossRefPubMed

Imaz I, Zegarra P, Gonzalez-Enriquez J, Rubio B, Alcazar R, Amate JM (2010) Poor bisphosphonate adherence for treatment of osteoporosis increases fracture risk: systematic review and meta-analysis. Osteoporos Int 21:1943–1951CrossRefPubMed

Sampalis JS, Adachi JD, Rampakakis E, Vaillancourt J, Karellis A, Kindundu C (2012) Long-term impact of adherence to oral bisphosphonates on osteoporotic fracture incidence. J Bone Miner Res 27:202–210CrossRefPubMed

McClung MR, Lewiecki EM, Cohen SB, Bolognese GC, Woodson AH et al (2006) Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 354:821–831CrossRefPubMed

Kamimura M, Nakamura Y, Ikegami S, Uchiyama S, Kato H, Taguchi A (2017) Significant improvement of bone mineral density and bone turnover markers by denosumab therapy in bisphosphonate-unresponsive patients. Osteoporos Int 28:559–566CrossRefPubMed

Kendler DL, Roux C, Benhamou CL, Brown JP, Lillestol M, Siddhanti S, Man HS, San Martin J, Bone HG (2010) Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy. J Bone Miner Res 25:72–81CrossRefPubMed

Nakamura T, Matsumoto T, Sugimoto T, Hosoi T, Miki T et al (2014) Clinical trials express: fracture risk reduction with denosumab in Japanese postmenopausal women and men with osteoporosis: denosumab fracture intervention randomized placebo controlled trial (DIRECT). J Clin Endocrinol Metab 99:2599–2607CrossRefPubMedPubMedCentral

Lewiecki EM (2009) Denosumab in postmenopausal osteoporosis: what the clinician needs to know. Ther Adv Musculoskelet Dis 1:13–26CrossRefPubMedPubMedCentral

Moen MD, Keam SJ (2011) Denosumab: a review of its use in the treatment of postmenopausal osteoporosis. Drugs Aging 28:63–82CrossRefPubMed

10.

Jamal SA, Ljunggren O, Stehman-Breen C, Cummings SR, McClung MR et al (2011) Effects of denosumab on fracture and bone mineral density by level of kidney function. J Bone Miner Res 26:1829–1835CrossRefPubMed

11.

Lipton A, Fizazi K, Stopeck AT, Henry DH, Brown JE et al (2012) Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials. Eur J Cancer 48:3082–3092CrossRefPubMed

12.

McClung MR, Lewiecki EM, Geller ML, Bolognese MA, Peacock M, Weinstein RL, Ding B, Rockabrand E, Wagman RB, Miller PD (2013) Effect of denosumab on bone mineral density and biochemical markers of bone turnover: 8-year results of a phase 2 clinical trial. Osteoporos Int 24:227–235CrossRefPubMed

13.

Jones AR, Sim IW (2020) Denosumab failure associated with escape from suppression of bone resorption (in Eng). Bone 131:115157CrossRefPubMed

14.

Baim S, Wilson CR, Lewiecki EM, Luckey MM, Downs RW Jr, Lentle BC (2005) Precision assessment and radiation safety for dual-energy X-ray absorptiometry: position paper of the International Society for Clinical Densitometry. J Clin Densitom 8:371–378CrossRefPubMed

15.

Soen S, Fukunaga M, Sugimoto T, Soen T, Fujiwara S et al (2013) Diagnostic criteria for primary osteoporosis: year 2012 revision. J Bone Miner Metab 31:247–257CrossRefPubMed

16.

Lodder MC, Lems WF, Ader HJ, Marthinsen AE, van Coeverden SC, Lips P, Netelenbos JC, Dijkmans BA, Roos JC (2004) Reproducibility of bone mineral density measurement in daily practice. Ann Rheum Dis 63:285–289CrossRefPubMedPubMedCentral

17.

Kushida K, Shiraki M, Nakamura T, Kishimoto H, Morii H et al (2004) Alendronate reduced vertebral fracture risk in postmenopausal Japanese women with osteoporosis: a 3-year follow-up study. J Bone Miner Metab 22:462–468CrossRefPubMed

18.

Soen S, Arai Y, Matsuda S, Emori K, Ikezaki T, Osawa M (2020) A 3-year postmarketing study on the safety and effectiveness of once-monthly risedronate in Japanese patients with osteoporosis. Osteoporos Sarcopenia 6:191–198CrossRefPubMedPubMedCentral

19.

Hagino H, Shiraki M, Fukunaga M, Nakano T, Takaoka K, Ohashi Y, Nakamura T, Matsumoto T (2012) Three years of treatment with minodronate in patients with postmenopausal osteoporosis. J Bone Miner Metab 30:439–446CrossRefPubMed

20.

Suzuki T, Nakamura Y, Kato H (2018) Efficacy, safety, and compliance of ibandronate treatment for 3 years in postmenopausal Japanese women with primary osteoporosis. Osteoporos Sarcopenia 4:69–72CrossRefPubMedPubMedCentral

21.

Tsai JN, Uihlein AV, Lee H, Kumbhani R, Siwila-Sackman E, McKay EA, Burnett-Bowie SA, Neer RM, Leder BZ (2013) Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial. Lancet 382:50–56CrossRefPubMedPubMedCentral

22.

Perazella MA, Markowitz GS (2008) Bisphosphonate nephrotoxicity (in Eng). Kidney Int 74:1385–1393CrossRefPubMed

23.

Ayasreh N, Fernandez-Llama P, Lloret MJ, Da Silva I, Ballarín J, Bover J (2013) Recombinant PTH associated with hypercalcaemia and renal failure (in Eng). Clin Kidney J 6:93–95CrossRefPubMed

24.

Freemantle N, Satram-Hoang S, Tang ET, Kaur P, Macarios D, Siddhanti S, Borenstein J, Kendler DL (2012) Final results of the DAPS (Denosumab Adherence Preference Satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women. Osteoporos Int 23:317–326CrossRefPubMed

25.

Tada M, Inui K, Sugioka Y, Mamoto K, Okano T, Koike T, Nakamura H (2016) Reducing glucocorticoid dosage improves serum osteocalcin in patients with rheumatoid arthritis-results from the TOMORROW study. Osteoporos Int 27:729–735CrossRefPubMed

26.

Kuroki Y, Kaji H, Kawano S, Kanda F, Takai Y, Kajikawa M, Sugimoto T (2008) Short-term effects of glucocorticoid therapy on biochemical markers of bone metabolism in Japanese patients: a prospective study. J Bone Miner Metab 26:271–278CrossRefPubMed

27.

Petranova T, Sheytanov I, Monov S, Nestorova R, Rashkov R (2014) Denosumab improves bone mineral density and microarchitecture and reduces bone pain in women with osteoporosis with and without glucocorticoid treatment. Biotechnol Biotechnol Equip 28:1127–1137CrossRefPubMedPubMedCentral

28.

Hirooka Y, Nozaki Y, Inoue A, Li J, Shiga T, Kishimoto K, Sugiyama M, Kinoshita K, Funauchi M, Matsumura I (2020) Effects of denosumab versus teriparatide in glucocorticoid-induced osteoporosis patients with prior bisphosphonate treatment. Bone Rep 13:100293CrossRefPubMedPubMedCentral

29.

Coin A, Sergi G, Benincà P, Lupoli L, Cinti G, Ferrara L, Benedetti G, Tomasi G, Pisent C, Enzi G (2000) Bone mineral density and body composition in underweight and normal elderly subjects. Osteoporos Int 11:1043–1050CrossRefPubMed

30.

Kobayakawa T, Miyazaki A, Saito M, Suzuki T, Takahashi J, Nakamura Y (2021) Denosumab versus romosozumab for postmenopausal osteoporosis treatment. Sci Rep 11:11801CrossRefPubMedPubMedCentral

31.

Kobayashi M, Sawada K, Yoshimura A, Yamamoto M, Shimizu A, Shimura K, Komura N, Miyamoto M, Ishida K, Kimura T (2020) Clinical effects of switching from minodronate to denosumab treatment in patients with postmenopausal osteoporosis: a retrospective study. BMC Womens Health 20:48CrossRefPubMedPubMedCentral

32.

Suzuki T, Nakamura Y, Kamimura M, Kato H (2018) Denosumab significantly improves lumbar spine bone mineral density more in treatment-naïve than in long-term bisphosphonate-treated patients. Bone Rep 8:110–114CrossRefPubMedPubMedCentral

33.

Miller PD, Pannacciulli N, Malouf-Sierra J, Singer A, Czerwiński E, Bone HG, Wang C, Huang S, Chines A, Lems W, Brown JP (2020) Efficacy and safety of denosumab vs bisphosphonates in postmenopausal women previously treated with oral bisphosphonates. Osteoporos Int 31:181–191CrossRefPubMed

34.

Langdahl BL, Libanati C, Crittenden DB, Bolognese MA, Brown JP et al (2017) Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial. Lancet 390:1585–1594CrossRefPubMed

35.

McClung MR (2016) Cancel the denosumab holiday. Osteoporos Int 27:1677–1682CrossRefPubMed

36.

Takeuchi T, Tanaka Y, Ishiguro N, Yamanaka H, Yoneda T, Ohira T, Okubo N, Genant HK, van der Heijde D (2016) Effect of denosumab on Japanese patients with rheumatoid arthritis: a dose-response study of AMG 162 (Denosumab) in patients with RheumatoId arthritis on methotrexate to Validate inhibitory effect on bone Erosion (DRIVE)-a 12-month, multicentre, randomised, double-blind, placebo-controlled, phase II clinical trial. Ann Rheum Dis 75:983–990CrossRefPubMed

37.

Ebina K, Hirao M, Hashimoto J, Hagihara K, Kashii M, Kitaguchi K, Matsuoka H, Iwahashi T, Chijimatsu R, Yoshikawa H (2018) Assessment of the effects of switching oral bisphosphonates to denosumab or daily teriparatide in patients with rheumatoid arthritis. J Bone Miner Metab 36:478–487CrossRefPubMed

38.

Pisani P, Renna MD, Conversano F, Casciaro E, Di Paola M, Quarta E, Muratore M, Casciaro S (2016) Major osteoporotic fragility fractures: Risk factor updates and societal impact (in Eng). World J Orthop 7:171–181CrossRefPubMedPubMedCentral

Titel: Risk factors for poor response to denosumab treatment in Japanese postmenopausal women with osteoporosis
verfasst von: Tokutaro Okawa
Motomi Okawa
Tatsuya Koike
Publikationsdatum: 08.08.2022
Verlag: Springer Nature Singapore
Erschienen in: Journal of Bone and Mineral Metabolism / Ausgabe 6/2022
Print ISSN: 0914-8779
Elektronische ISSN: 1435-5604
DOI: https://doi.org/10.1007/s00774-022-01357-z

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Reizdarmsyndrom: Diäten wirksamer als Medikamente

29.04.2024 Reizdarmsyndrom Nachrichten

Bei Reizdarmsyndrom scheinen Diäten, wie etwa die FODMAP-arme oder die kohlenhydratreduzierte Ernährung, effektiver als eine medikamentöse Therapie zu sein. Das hat eine Studie aus Schweden ergeben, die die drei Therapieoptionen im direkten Vergleich analysierte.

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Introduction

Materials and methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2022

The crosstalk between LINC01089 and hippo pathway inhibits osteosarcoma progression

Unravelling hip–spine bone mineral density discordance in people living with HIV

Bone mass and biomarkers in young women with anorexia nervosa: a prospective 3-year follow-up study

Risk factors for subchondral insufficiency fracture of the femoral head in renal transplant patients

Cortical thickness mapping at segmented regions in the distal radius using HR-pQCT